Methyladenosine Modification in RNAs: Classification and Roles in Gastrointestinal Cancers

Qinghai Li1,2, Weiling He1,2* and Guohui Wan3*

1 Department of Gastrointestinal Surgery, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China, 2 Center for Precision Medicine, Sun Yat-Sen University, Guangzhou, China, 3 School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China

Cellular ribonucleic acids (RNAs), including messenger RNAs (mRNAs) and non-coding RNAs (ncRNAs), harbor more than 150 forms of chemical modifications, among which methylation modifications are dynamically regulated and play significant roles in RNA metabolism. Recently, dysregulation of RNA methylation modifications is found to be linked to various physiological bioprocesses and many human diseases. Gastric cancer (GC) and colorectal cancer (CRC) are two main gastrointestinal-related cancers (GIC) and the most leading causes of cancer-related death worldwide. In-depth understanding of molecular mechanisms on GIC can provide important insights in developing novel treatment strategies for GICs. In this review, we focus on the multitude of epigenetic changes of RNA methyladenosine modifications in gene expression, and their roles in GIC tumorigenesis, progression, and drug resistance, and aim to provide the potential therapeutic regimens for GICs.

Keywords: RNA, methylation modification, m6A, m6Am, m1A, gastrointestinal cancers

INTRODUCTION

With the deepening of genetics research and the emergence of epigenetics, many reversible chemical modifications have been identified. In RNAs, human cells undergo various forms of modification with different levels (1–3). The constitutive non-coding RNAs (ncRNAs) are known to contain larger number of pseudouridine (Ψ) and 2′-O-methylations (2′-OMe or Nm) modifications (1). In addition, various modifications are identified in the regulatory ncRNAs including small ncRNAs (snRNAs), long ncRNAs (lncRNAs), and circular RNAs (circRNAs) and play important roles in metabolism and functions (4–7). However, owing to the spatiotemporal specificity of regulatory ncRNAs in various tissues, the detailed and conserved biological characteristics of most RNA modifications are unclear. As for mRNAs, internal methylation modifications have been recently revealed with help of the advanced detection and analysis technologies as well as the common modification of N7-methylguanosine (m7G) cap in the 5′ terminal region of mRNA (8–12). The most prevalent and crucial internal methylation form in mRNAs is N6-methyladenosine (m6A) modification that firstly identified in 1974 in eukaryotic cells (12–16), while the other major forms include N6,2′-O-dimethyladenosine (m6Am), N1-methyladenosine (m1A), 2′-OMe, and 5-methylcytosine (m5C).
Gastric cancer (GC) and colorectal cancer (CRC) are the most common gastrointestinal-related cancers (GICs). CRC is the fourth most commonly diagnosed cancer (6.1%) and the second leading cause of cancer death (9.2%) worldwide, while GC is the sixth diagnosed cancer and the third cause of cancer death (8.2%) (17). In-depth research on molecular mechanisms in GICs can provide important insights in developing novel treatment strategies for GICs.

Recently, RNA methylation has been found to play critical roles in various bioprocesses including embryonic development, RNAs metabolism, gene expression regulation, and its aberrant roles in various bioprocesses including embryonic development, progression, and drug resistance, and aim to provide the potential therapeutic regimens for GICs.

**M6A MODIFICATION**

**Biological Characteristics of m6A Modification**

Although m6A is an “old” modification form that was firstly discovered in 1974 (13, 14), it had not gained enough attention until two breakthrough methods developed in 2011. The first breakthrough is the discovery of FTO (fat mass and obesity-associated protein), the first mammalian m6A demethylase in 2011 (19) and AlkB homolog 5 (ALKBH5), another demethylase in mouse fertility and spermatogenesis in 2013 (20), which proves that the m6A modification is a dynamic process and regulated by both methyltransferase and demethylase. The second breakthrough is that the transcriptome-wide distribution of m6A modification has been well revealed at ~100–200-nucleotide resolution in 2012 owing to the development of methylated RNA immunoprecipitation sequencing (MeRIP-seq) or m6A-seq technology (21, 22). Since then, other detection methods such as single-nucleotide resolution, antibody-independent, or isoform characterization analysis, have emerged as powerful tools for the m6A analysis. These tools mainly include site-specific cleavage and radioactive labeling followed by ligation-assisted extraction and thin layer chromatography (SCARLET) (23), m6A individual-nucleotide-resolution crosslinking and immunoprecipitation (miCLIP) (4), m6A level and isoform characterization sequencing (m6A-LAIC-seq) (24), deamination adjacent to RNA modification targets sequencing (DART-seq) (25), MAZTER-seq (26), m6A-sensitive RNA-endonuclease-facilitated sequencing (m6A-REF-seq) (27), m6A-table-seq (28), m6A-SEAL (29), and the third-generation sequencing technologies (30). However, these methods have shortcomings such as inconvenient procedures (radioisotope p32), high cost, unavailability to distinguish m6A and mAm, and detection limits of a certain motif.

As reported, m6A modification occurs in almost all transcripts with the ratio of m6A/A in mRNAs ranges from 0.2 to 0.5% (15, 24, 31, 32). The distribution of m6A modifications are not random but strictly restricted, where they are commonly confined in the consensus sequence RRACH that refers to [G/A/U][G>A]/m6AC[U>A>C] motif (7, 21, 33) and enriched in the long internal exons and regions next to the 3’ untranslated region (3’ UTR) within mRNAs (21, 22, 27). The deposition of m6A in the introns of the precursor mRNAs (pre-mRNAs) and in primary microRNAs (pri-miRNAs), which means that the m6A modification can be regulated either before or simultaneously with RNAs splicing and processing (34) (Table 1, Figure 1).

**Components of the m6A Modification System**

**Writers**

In 1994, Bokar and colleagues characterized a multicomponent complex of mRNA m6A methyltransferases (MTases, “writers”) that extracted from the nucleus, which is composed of three components with ~30 kDa, ~200 kDa, and ~875 kDa, respectively. The ~200 kDa component contains the S-adenosyl-L-methionine (SAM)–binding site on a 70 kDa subunit and the ~875 kDa component may has affinity for mRNA strands (35, 36). Subsequently the SAM-binding ability of the 70 kDa subunit and was named as MT-A70 (now known as methyltransferase-like 3 (METTL3) (37). Hereafter,

| TABLE 1 | The biological characteristics of methyladenosine modification in mRNA. |
|---------|---------------------------------------------------------------|
| MT      | Peaks/sites                      | Ratio          | Distribution               | Motif                                    | Detection methods                                      |
| m6A     | -10,000–20,000                  | -0.2–0.5%      | Introns, long internal exons, near stop codon and 3’ UTR | RRACH motif ([G/A/U][G>A] m6AC(U>A>C)) | MeRIP-seq, SCARLET, miCLIP, SELECT, m6A-LAIC-seq, m6A-lable-seq, m6A-SEAL, and so on |
| m6Am    | -500–1,000                      | -0.01–0.02%    | Cap+1/2, 5’UTR             | BGMmAm motif (B represents C, G or U) | m6A-SEAL                                                  |
| m1A     | -500–5,000 (but need more evidence) | -0.01–0.16%  | 5’ UTR, near start codons or TSS | GGAU codon and GUICRA RNA-like motif (both not obviously) | m6A-SEAL combined method, m1A-ID-seq, m1A-MAP |

**MT, modification types; m6A, N6-methyladenosine; m6Am, N6,2’-O-dimethyladenosine; m1A, N1-methyladenosine; A, adenosine; U, uridine; C, cytidine; G, Guanosine; 5’UTR, 5’ untranslated region; 3’UTR, 3’ untranslated region; TSS, transcription start site; MeRIP-seq, m6A RNA immunoprecipitation followed by high-throughput sequencing; SCARLET, site-specific cleavage and radioactive labeling followed by ligation-assisted extraction and thin layer chromatography; miCLIP, m6A individual-nucleotide-resolution crosslinking and immunoprecipitation; SELECT, single-base elongation and ligation-based qPCR amplification method; m6A-LAC-seq, m6A level and isoform characterization sequencing; DART-seq, deamination adjacent to RNA modification targets sequencing; m6A-REF-seq, m6A-sensitive RNA-endonuclease-facilitated sequencing; CITS miCLIP, the crosslinking-induced truncation sites-based miCLIP.
methyltransferase-like 14 (METTL14) has been identified as the homologue of METTL3 and functions as another core component of the complex (38–41). Both METTL3 and METTL14 are highly conserved within the (D/E)PP(W/L) active site and the SAM$^-$ binding motif in mammals with ~35% and ~43% sequence homology of the MTase domain in mouse and human respectively (39, 40, 42). Despite METTL3 and METTL14 exhibit relatively weak MTase activity when acting alone, the METTL3-METTL14 complex with a stoichiometric ratio of 1:1 shows a much higher catalytic activity. The primary functions of METTL3 in the complex is to catalyze methyl-group transfer, whereas METTL14 is the aide that helps MTase complex positioning by identifying the histone H3 trimethylation at Lys36 (H3K36me3) (in co-transcriptional manner), and offers a structural scaffold that enhancing the catalytic activity of METTL3, even though METTL14 can affect the m6A levels more significantly than METTL3 (40, 41, 43–46).

Recent studies have identified other associated proteins in MTase complex. Schwartz et al. (50) found that KIAA1429 (VIRMA) is required for the m6A methylation in human cells, and Yue et al. further demonstrated that KIAA1429 can play a role as region-selective factors by recruiting the catalytic core components METTL3/METTL14/WTAP to 3'$UTR and near the stop codon (51). They also highlighted the importance of Cbl proto oncogene like 1 (HAKAI or CBLL1) and zinc finger CCCH-type containing 13 (ZC3H13) in the full methylation program, and ZC3H13 is required for the nuclear localization of MTase complex (51, 52). The RNA-binding motif protein 15 (RBM15) and its parologue RBM15B are also identified as the regulators of m6A modification in mRNAs (53). In addition, the transcription factors zinc finger protein 217 (ZFP217), SMAD2/3, and CAAT-box binding protein (CEBPZ) are found to mediate the m6A deposition in mRNAs (54–56). Some other m6A methyltransferases such as METTL5, METTL16, and zinc finger CCHC-type-containing 4 (ZCCHC4) are also indispensable for m6A formation, especially in ncRNAs and rRNAs (57–59).

![FIGURE 1](image_url)

**FIGURE 1** | Distribution and chemical structure of methylation modifications. (A) m$^6$Am and m$^1$A are mainly enriched in the 5'$UTR, whereas m$^8$A is concentrated in the 3'$UTR. (B) Demethylation of m$^6$A is in a stepwise manner, the intermediate of hm$^6$A is the direct oxidation product of m$^6$A, while f$^6$A is the further oxidized product of hm$^6$A, and the final product is A. (C) The demethylation process of m$^6$Am is similar to that of m$^6$A, but the potential intermediate f$^6$Am has not been reported. (D) The demethylation process of m$^1$A remains unclear due to the special chemical bond. UTR, untranslated region; CDS, coding sequence; FTO, fat mass and obesity-associated protein; ALKBH3, AlkB homolog 3; A, adenosine; Am, 2'-O-methyladenosine; m$^6$A, N$^6$-methyladenosine; hm$^6$A, N$^6$-hydroxymethyladenosine; f$^6$A, N$^6$-formyladenosine; m$^6$Am, 2'-O-dimethyladenosine; hm6Am, N$^6$-hydroxymethyl, 2'-O-methyladenosine; m$^1$A, N$^1$-methyladenosine.
Erasers

FTO was recognized as the first m6A eraser (19), which was originally discovered in 1999 and was officially named in 2007 (60, 61). Bioinformatics analysis revealed that FTO is one of the non-heme Fe(II)/α-ketoglutarate (α-KG)-dependent dioxygenases (also known as non-heme Fe(II)/2-oxoglutarate (2-OG)-dependent dioxygenases) (62). FTO was shown to mediate the demethylation of N6-methyladenosine in single-stranded DNA and N3-methyluridine in single-stranded RNA in vitro (63, 64). In 2011, Jia et al. (19) proved that FTO could participate in the demethylation process of nuclear RNAs in nuclear speckles, and Fu et al. (65) further revealed the role of FTO in the detailed process of RNA m6A demethylation in 2013. They found that FTO oxidizes m6A in a stepwise manner, and the intermediate of N6-hydroxymethyladenosine (hm6A) is the direct oxidation product of m6A and turns into the form of N6-formyladenosine (f6A). The final products of m6A demethylation are unmethylated adenosine and formaldehyde (from hm6A) or formic acid (from f6A). Interestingly, the half-lives of hm6A and f6A are suggested to be ~3 h under physiological conditions, meaning that the decomposing of hm6A and f6A do not occur simultaneously with the oxidation of m6A.

As for ALKBH5, the second m6A demethylase identified so far in mammals, belongs to the AlkB family, a class of the non-heme Fe(III)/α-ketoglutarate (α-KG)-dependent dioxygenases superfamily which was originally shown to revert DNA base damage by catalyzed oxidative demethylation of N-alkylated nucleic acid bases (20, 66–68). Structure analysis indicates that ALKBH5 has comparable catalytic activity with FTO, whereas AlkB has low level (~17%) of the amino acid sequence identity to FTO (62, 69). While FTO can demethylate on both single-stranded RNA/DNA and double-stranded RNA/DNA (albeit low) (19, 70), ALKBH5 only demethylate the single-stranded RNA/DNA with the sequence preference (the activity in the consensus sequence is twice that in other sequences), which may be due to the fact that ALKBH5 mainly localizes in nuclear speckles and acts in regulating the nuclear export and metabolism of RNAs (20).

Readers

There are four main readers selectively bind the m6A-containing mRNAs in the nucleus. In 1998 Imai et al. (71) isolated a novel RNA splicing-related protein YT521 by using yeast two-hybrid screens system with rat transformer-2-beta1 (RA301) as bait, and Hartmann et al. identified a homologous protein YT521-B by using htra2-beta1 as bait (72). Subsequently, the YT521-B homology (YTH) domain was defined as a new protein family, the YTH (YT521-B homology) domain containing protein family, and now YT521-B is known as the YTH domain-containing protein 1 (YTHDC1) (73). YTHDC1 localizes in a subnuclear structure named YT bodies that contain transcriptionally active sites and are close to other subnuclear compartments such as speckles and coiled bodies (74). Structure analysis demonstrated that the GG(m6A)C sequence is the preferred binding site for YTH domain in YTHDC1 (75, 76). Since its localization is adjacent to the nuclear speckles, YTHDC1 is found to participate in pre-mRNAs splicing containing m6A sites, and mediate its nuclear export. YTHDC1 facilitates the splicing pattern of exon inclusion in targeted mRNAs by recruiting pre-mRNA splicing factor SRSF3 (SRp20) and inhibiting SRSF10 (SRp38), by which it changes alternative splicing patterns via modulating splice sites selection in a concentration-dependent manner (72, 77). In addition, YTHDC1 is found to interact with the nuclear RNA export factor 1 (NXF1) to promote the nuclear export of the m6A-containing mRNAs (78).

The other three readers in the nucleus belong to the heterogeneous nuclear ribonucleoprotein (hnRNP) family that is composed of more than 20 members. HnRNP protein contains at least one RNA-binding domain with RNA recognition motif (RRM), K-Homology (KH) domain, or an arginine/glycine-rich box (79). Recently, their role as the “reader” of m6A remains controversial. Previously, Alarcon et al. showed that hnRNPA2/B1 can directly bind with m6A by matching the m6A consensus motif and regulate the alternative splicing of its mRNA targets (80), whereas Wu et al. (81) suggested that hnRNPA2/B1 may interact with m6A via the “m6A switch” mechanism instead of directly recognizing the m6A-containing bases, by which the m6A controls the RNA-structure-dependent accessibility of the RNA-binding domains to affect the RNA-protein interactions for biological regulation. In addition, heterogeneous nuclear ribonucleoprotein C (hnRNPC), an abundant nuclear RNA-binding protein, and heterogeneous nuclear ribonucleoprotein G (hnRNPG), a low-complexity protein, interact with the m6A-containing mRNAs via the similar “m6A switch” mechanism (6, 82, 83).

Besides readers in the nucleus, four members of the YTH domain-containing proteins are identified in the cytoplasm that are involved in mRNAs metabolism via interacting the m6A with their hydrophobic pocket, an aromatic cage formed by tryptophan residues, within the YTH domain (76, 84, 85). YTHDF1, YTHDF2, and YTHDF3 are highly homologous, and all contain a ~40 kDa low-complexity domain and a prion-like domain (86). The most abundant YTHDF paralog, YTHDF2, is the first member to be fully studied, where it was originally implicated in regulating the instability and the decay of the m6A-containing mRNAs by localizing the complex of YTHDF2-m6A-mRNA from the translatable pool to the processing bodies (P-bodies) (87). However, another group demonstrated that the P-bodies only act an indirect role in the decay of m6A-containing RNAs since no direct interaction between YTHDF2 and GW182, the core component of the P-bodies was found (88). Subsequent study revealed that YTHDF2-m6A-mRNA complex was located in the stress granules or neuronal RNA granules through the phase separation mechanism upon stress stimulation and was subject to compartment-specific regulations (89).

Although all YTHDF proteins can recruit CCR4-NOT and promote mRNA deadenylateylation (88). YTHDF1 is the only member which is reported to facilitate translation by binding to the RRACH motifs instead of the flanking sequence that cluster around the stop codon and subsequently recruiting translation initiation factor (eIF) and ribosome. The association of YTHDF1 with translational initiation machinery...
may be depend on the loop structure mediated by eIF4G and the interaction of YTHDF1 with eIF3 (90). Besides, YTHDF1 is found to bind to the nascent methylated mRNAs earlier than YTHDF2, which suggests that the translation of mRNAs occurs before their decay under various physiological conditions (90). As for YTHDF3, it plays dual functions in m^6^A-containing mRNAs metabolism by either promoting the translation of the targeted mRNAs via interaction with YTHDF1 (91), or accelerating the decay of the targeted mRNAs via interaction with YTHDF2 (92). Controversially, Jaffrey et al. (93) proposed another brand new but opposite model for the role of YTHDF proteins in regulating m^6^A-containing mRNAs. They demonstrated that YTHDF proteins binded with the same mRNA rather than different mRNAs and act redundantly to co-mediate mRNA degradation, and the stability of mRNA fails to restore until all YTHDF1,2,3 are depleted simultaneously (Figure 2).

The fifth member of the YTH protein family is YTHDC2, which is different from the other cytoplasmic “readers”. YTHDC2 has a large molecular mass of ~160 kDa and contains the helicase domain (94). YTHDC2 is previously reported to enhance the translation efficiency of its targets and decrease their mRNA abundance by binding to the m^6^A site at its consensus motif and influencing the mRNA secondary structures (94, 95). However, a latest report indicated that YTHDC2 could also reduce the m^6^A-containing mRNAs stability and inhibit gene expression in certain situations (96).

The insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs, originally called IMPs) family, including IGF2BP1/2/3, which is initially recognized as an IGF2 translation inhibitor (97), belongs to a new family of m^6^A readers that mainly prevent the m^6^A-containing mRNAs from degradation in cytoplasm (98). IGF2BPs are composed of two RRM domains and four KH domains, and preferentially bind the m^6^A-modified mRNAs through recognizing the consensus GG(m^6^A)C sequence and facilitate the stability and translation of thousands of its mRNA targets by co-localizing in the P-bodies or stress granules, thus upregulating the gene expression in globally (98). Recently, ELAV like RNA binding protein 1 (ELAVL1, also known as HuR), matrin 3 (MATR3), and poly (A) binding protein cytoplasmic 1 (PABPC1) have been identified as the cofactors of IGF2BPs that promote the stability of m^6^A-containing mRNAs simultaneously.

In addition, fragile X mental retardation protein (FMRP) and proline rich coiled-coil 2 A (PRRC2A) are reported to play a role as the reader/stabilizer of the m^6^A-containing mRNAs (99, 100). METTL3 is found to associate with ribosomes and promote translation in some cancers when it localizes in the cytoplasm

---

**FIGURE 2** | Two controversial models for the function of DFs in regulating m^6^A-containing mRNAs. In model 1 (A, C), DF1 and DF2 bind to different mRNAs and promote their translation and degradation respectively. In model 2 (B, D), DFs bind to the same mRNA rather than different mRNAs simultaneously and act redundantly to co-mediate mRNA degradation but not translation. The stability of mRNA can be restored only when DF1-3 are depleted simultaneously. DFs, YTHDF proteins; DF1, YTHDF1; DF2, YTHDF2; DF3, YTHDF3; m^6^A, N^6^-methyladenosine.
The m^6^Am modification occurs on the basis of Am that formed previously purified by HENMT1 and FTSJ3 (110, 111), and its WW domain, also called cap-specific methyltransferase (CAPAM) (106, 112, 113). Unlike the m^6^A methyltransferase, CAPAM recognizes the mRNA cap and it can be further modified at the N^6^ position by methylation to generate m^6^Am (92% chance of being modified), where the structure of m^6^A-ppp5^’^NmpNp and the m^6^A-ppp5^’^NmpNp comprises 20–30% of all the structures (105, 106) (Fig. 1). The second nucleotide can harbor a similar modification but with a lower frequency, whereas m^6^A rarely located in the third nucleotide and m^6^A or A has not been found at the first nucleotide position (107). In addition, there are ~6% of the m^6^A occurs outside the 5’UTR, and motif analysis reveals that the m^6^A mainly deposit in a novel motif BCm^6^Am (B represents C, G, or U) that enriched in the transcription start site (TSS), rather than the canonical m^6^A motif RRACH (4, 108, 109). Molinie et al. used liquid chromatography-mass spectrometry (LC-MS) to quantify of the m^6^Am in mRNAs and found that mRNAs contain ~3 m^6^Am nucleotides per 10^6^ nucleotides, revealing a 33-fold level of the m^6^A modification than the m^6^A in mRNAs (24). Consistently, Liu et al. (108) confirmed the m^6^Am/A ratio of total RNAs and mRNAs ranges from 0.0036 to 0.0169% and from ~0.01 to 0.02% respectively. Currently, the m^6^Am transcriptome-wide expression can only be detected by the methods of the crosslinking-induced truncation sites-based miCLIP (CITS miCLIP) and the refined RIP-seq, and an antibody-free enzyme-assisted chemical approach termed m^6^A-SEAL (29) (Table 1).

### Components of m^6^Am Modification System

#### Writer
The formation of m^6^Am occurs on the basis of Am that formed by the MTases HENMT1 and FTSJ3 (110, 111), and its modification system rarely known yet. The m^6^Am MTase was previously purified with a molecular weight of ~65 KD in 1978, and phosphorylated CTD-interacting factor 1 (PCIF1) was recognized as the first m^6^Am MTase in 2019. It was named by its ability to directly bind to the phosphorylated carboxyl-terminal domain (CTD) of RNA polymerase II (RNAP II) by its WW domain, also called cap-specific adenosine methyltransferase (CAPAM) (106, 112, 113). The m^6^A core readers that work in the form of a methyltransferase complex, PCIF1 is a "stand-alone" RNA MTase and functions in an m^6^G cap-dependent manner. Recently, METTL4 was reported to catalyze m^6^Am methylation in the U2 snRNA (114).

#### Eraser
FTO, the first m^6^A demethylase, was found to mediate the demethylation of m^6^A in the similar manner to that of m^6^A (115, 116). The intermediate of N^6^-hydroxymethyl, 2’-O-methyladenosine (hm^6^Am) was detected as well as the end product Am. Intriguingly, although both m^6^A and m^6}Am can be catalyzed by FTO, the priority between them is still controversial. Zhang et al. (116) showed that FTO displays the first m^6^Am MTase in 2019. It was named by its ability to directly bind to the phosphorylated carboxyl-terminal domain (CTD) of RNA polymerase II (RNAP II) by its WW domain, also called cap-specific adenosine methyltransferase (CAPAM) (106, 112, 113). The m^6^A core readers that work in the form of a methyltransferase complex, PCIF1 is a "stand-alone" RNA MTase and functions in an m^6}G cap-dependent manner. Recently, METTL4 was reported to catalyze m^6^Am methylation in the U2 snRNA (114).
m^6^Am among cells where the m^6^A is most affected despite it prefers the m^6^Am in vitro by the cellular cap-binding proteins (117). Controversially, Mauer et al. (115) found that FTO does not efficiently demethylate m^A^ but preferentially demethylates m^6^Am. They further showed that ALKBH5 did not affect the m^6^Am in mRNAs and stated that FTO may targets the m^6^Am whereas ALKBH5 targets the m^6^A in vivo.

**Functions of the m^6^Am**

Currently, there is no m^6^Am reader that has been identified, and its function remains controversial. The first work showed that the m^6^Am stabilizes mRNA by preventing the mRNA-decapping enzyme DCP2-mediated decapping and microRNA-mediated mRNA degradation (115), and it was confirmed by Mauer's work (109). However, Sendinc et al. (118) revealed that m^6^Am fails to alter mRNA transcription and stability, and negatively impacts cap-dependent translation. Akichika et al. (106) further showed that the m^6^Am facilitates the translation of capped mRNAs. The direct readers of the m^6^Am are under investigated (Table 2).

**THE m^1^A MODIFICATION**

**Biological Characteristics of the m^1^A Modification**

The m^1^A modification was firstly discovered in the total mixed RNA samples in 1961 (119) and was found that it can rearrange into the m^6^A under alkaline conditions (Dimroth rearrangement) in 1968 (120). Subsequently, accumulating evidence has shown that the m^1^A occurs in rRNAs and tRNAs where the m^1^A is typically found at position 9 and 58 in the tRNA TΨC-loop and plays key roles in the structure formation and function execution via its methyl adduct and positive charge (121, 122). By using of the liquid chromatography-tandem mass spectrometry (LC-MS/MS), the ratio of m^1^A/A in the mammalian cell lines and tissues can be easily detected, which ranging from approximately 0.015 to 0.054% and up to 0.16% (123, 124). Hereafter, He et al. (123) used the combined method of an antibody-based approach called m^1^A-seq and an orthogonal chemical method based on Dimroth rearrangement to obtain a more detailed distribution of m^1^A. They found that the distribution pattern and the peaks of the m^1^A are highly conserved in the samples from multiple sources, and the m^1^A enrich in the 5' UTR, near the start codons or TSS, which is similar to that of m^6^Am. Yi et al. further supported the finding by original technology m^1^A-ID-seq (124). In addition, single-nucleotide resolution analysis (m^1^A-MAP) showed that the m^1^A lacks of obvious preference to certain motif, but the GCA codon and GUUCRA tRNA-like motif are frequently modified, and no m^1^A is detected in the AUG start codon (123, 125). Finally, Safra et al. reported 15 m^1^A sites in mRNAs and lncRNAs (126) (Table 1) (Figure 1).

**Components of m^1^A Modification System**

**Writers**

Although a variety of the m^1^A MTases, including tRNA methyltransferase 10C (TRMT10C), TRMT6/61A, TRMT61B, base MTase of 25S RNA (BMT2), MTR1, and nucleomethylin (NML), have been discovered, most of them catalyze the sites on tRNAs or rRNAs (122, 127–130). Li et al. unveiled that TRMT6/61A is able to methylate the m^A^ sites that are confined in GUUCRA tRNA-like motifs in mRNAs, and some of the mitochondrial (mt)-mRNAs are the target of TRMT61B (125). In addition, Safra et al. (126) have identified that a single m^1^A site in the mt-ND5 mRNA which is catalyzed by TRMT10C. Nonetheless, there is no direct specific m^1^A writer has been identified for mRNA yet.

**Erasers**

The m^A^ demethylases are found to only catalyze tRNAs so far. He et al. (131) showed that the human homolog of E. coli AlkB ALKBH1 is an important eraser that catalyzes the demethylation of the m^A^ in tRNAs in 2016, and FTO, was proven to mediate the m^A^ demethylation in tRNAs (117). However, neither ALKBH1 nor FTO mediates the removal of the methyl group from m^1^A in mRNAs. Recently, another demethylase ALKBH3 was shown to have a strong preference for single stranded DNA/RNA and the ability of repairing methylation damage to RNA in vitro in both tRNAs and mRNAs (123, 124, 132, 133). Yi et al. (124) further showed that ALKBH3 has minimal sequence preference and acts globally in the transcriptome.

**Functions of m^1^A**

The process of eukaryotic protein translation, especially the initiation step of translation, is strictly regulated in cells. Structure analysis showed that the secondary structure in the 5'UTR which is the target of the initiation factors such as elf4F/4A/B/H complex can affect the efficiency of the initiation of translation and the early elongation by impeding the binding and movement of the 40S ribosome (134, 135). He et al. (123) suggested that the m^1^A plays a positive role for the translation initiation in mammalian mRNAs, which is further supported by Li et al. (125). Mechanically, the m^1^A may inhibit Watson-Crick base pairing or introduce charge-charge interactions, leading to the alteration of the secondary/tertiary structure of 5'UTR in mRNAs. Potential readers specifically bound to the m^1^A in mRNAs are supposed to promote the initiation of translation, which is analogous to the role of YTHDF1 in translation enhancement. However, there are controversial reports showed that the m^1^A can repress the translation of mRNAs, especially mt-mRNAs while the underlying mechanism remains to be explored (126). In addition, the m^1^A is found to promote mRNA degradation by interacting with its potential readers YTHDF2/3 (136, 137) (Table 2).

**LINKS WITH GASTROINTESTINAL CANCERS AND POTENTIAL THERAPEUTIC STRATEGIES**

Under normal physiological condition, methylation modification is precisely modulated by the methyltransferases and demethylases, and involved in regulating alternative splicing, nuclear export,
stability, translation, or degradation of the methylated RNAs, thereby affecting cell self-renew, cell proliferation, and cell differentiation. Recently, accumulating studies have revealed that abnormality in RNA methylation led by mutations or dysregulation that cause the gain or the loss of methylation sites are closely related to the initiation, progression metastasis, and suppression of various tumors including GICs (138).

**Aberrant Writers in Gastrointestinal-Related Cancers**

The writer, METTL3, is found to be upregulated in GC patients with poor prognosis, which is caused by the P300-mediated H3K27 acetylation activation in the promoter of METTL3 and mediation by the transcription factor GFI1 (139–143). Yue et al. (139) have identified the zinc finger MYM-type containing 1 (ZMYM1) mRNA as the direct target of METTL3. Mechanistically, the reader ELAVL1 binds to the m^6^A sites within ZMYM1 mRNA and enhances the stability of ZMYM1. The induced ZMYM1 further inhibits the expression of E-cadherin by forming a complex of CtBP/LSD1/CoREST/ZMYM1 in the promoter region of E-cadherin, thus stimulating the epithelial-mesenchymal transition (EMT) and promoting metastasis of GC. In another report, the m^6^A modification of hepatoma derived growth factor (HDGF) mRNA can be induced by high level of METTL3, and recognized by the reader IGF2BP3 to promote its stability. The upregulated HDGF could further facilitate tumor angiogenesis and increase glycolysis in GC, which in turn enhance the tumor growth and liver metastasis (140). Additionally, the mRNAs of pre-protein translocation factor (SEC62), ARHGAP5, and MCM5 and MCM6 (the component molecules in the MYC pathway) are highly modified by the aberrant METTL3, and led to the acceleration of GC progression (141, 143, 144).

Upregulated METTL3 in CRC primary or metastatic tissues is highly associated with unfavorable outcomes (145–150). One potential mechanism mediated by upregulated METTL3 is ceramide glycosylation that generates glycosphingolipids (particularly globotriaosylceramide) and activates cSrc and β-catenin signaling (151). Li et al. (145) unveiled that higher METTL3 expression in CRC facilitates the methylation of SRY (sex determining region Y)-box 2 (SOX2) mRNA, and the reader IGF2BP2 further recognized the m^6^A-containing SOX2 mRNA and induced the expression level of SOX2 protein. SOX2 was previously reported to control the properties of the stem cells and enhanced cell proliferation and invasion in squamous cell carcinoma (152). While in CRC, highly expressed SOX2 regulates its downstream targets, including cyclin D1 (CCND1), MYC (mainly referred to as c-Myc), and POU class 5 homeobox 1 (POU5F1), and promoted their expression levels, thus upregulating CD133, CD44, and epithelial cell adhesion molecule (EpCAM). Shen et al. (148) found that METTL3 can directly interacts with the 5′/3′UTR regions of Hexokinase 2 (HK2) mRNA and the 3′UTR region of Glucose transporter type 1 (GLUT1, also SLC2A1) mRNA, and subsequently stabilized their mRNAs and activated the glycolysis pathway in CRC cells in a IGF2BP2- or IGF2BP2/3-dependent manner. In addition, upregulated METTL3 could facilitate CRC cell proliferation, progression, and metastasis by various signaling pathways including miR-1246/SPRED2/MAPK signaling pathway, p38/ERK pathway, and cyclin E1 (CCNE1) cell proliferation pathway (147, 149, 150).

Analogously, the high level of other writers WTAP and RBM15 also predicts poor prognosis for GC (153–155) Li et al. found that WTAP could be served as an independent predictor of GC and its high expression is closely related to the low T lymphocyte infiltration and T cell-related immune response (154).

Intriguingly, the writer METTL14 is reported to be downregulated in GC and CRC patients (139, 156). Zhang et al. (156) unveiled that METTL14 suppression may cause activation of the Wnt and PI3K-Akt signaling and thus promote GC progression. While Yang et al. (157) have revealed that the downregulated METTL14 is associated with the poor outcomes of CRC patients through up-regulating oncogenic lncRNA XIST. Specifically, the m^6^A level within lncRNA XIST is reduced as METTL14 suppression, which could lead to the RNA degradation and decay mediated by the m^6^A reader YTHDF2. The abundant lncRNA XIST due to downregulation of METTL14 acts as a carcinogen and promote cell proliferation and metastasis in CRC (158). Additionally, the downregulated METTL14 affects the m^6^A level in pri-miR-375, by which it decreased the binding of DGC8 to pri-miR-375 and results in the reduction of mature miR-375. The reduction of miR-375 causes induced level of Yes-associated protein 1 (YAP1) and SP1, and ultimately leads to cell growth in CRC via miR-375/YAP1 pathway and cell invasion via miR-375/SP1 pathway (159).

**Aberrant Erasers in Gastrointestinal-Related Cancers**

FTO, the first mammalian m^6^A demethylase and the only m^6^A demethylase currently discovered, is found to mediate the progression in GICs. FTO was reported to serve as an independent prognostic marker due to its frequently higher expression in high-risk scores subtype of GC (153, 155, 160). Other erasers ALKBH3 and ALKBH5 are also upregulated in GC, and ALKBH5 is found to promote the invasion and metastasis of GC by interacting with the lncRNA NEAT1 (nuclear paraspeckle assembly transcript 1) (155, 161, 162).

However, the expression levels of ALKBH5 and FTO in CRC are still controversial (146). From The Cancer Genome Atlas (TCGA), the Gene Expression Omnibus (GEO) database, and the Human Protein Atlas, ALKBH5 shows weak expression in CRC tissues compared to the normal tissues, and FTO shows no significant difference between CRC tissues and normal tissues. Whereas Wu et al. revealed a potential CRC-promoting mechanism via the ALKBH5/m^6^A/RP11/hnRNPA2B1/E-ligases/Zeb1 axis (163). They found that lncRNA RP11 in CRC is highly expressed and associated with the CRC stage in patients, by which lncRNA RP11 is regulated in an m^6^A-dependent manner and negatively correlated with ALKBH5 although METTL3 is elevated in CRC patients. Mechanistically, m^6^A-containing RP11 can interact with the reader hnRNPA2B1 and
bind to its downstream targets, two E3-ligase mRNAs Siah1 and Fbxo45 to accelerate their decay. The reduced Siah1 and Fbxo45 further downregulates the EMT-transcription factors Zeb1, and ultimately leads to the development of CRC. In addition, Relier et al. (164) showed that low expression of FTO in CRC cells causes increase of the m^6^Am levels in mRNAs and results in the enhanced malignancy and chemo resistance in CRC cells, which can be partially reversed by inhibition of PCIF1.

**Aberrant Readers in Gastrointestinal-Related Cancers**

Emerging studies have reported the upstream regulatory mechanisms that lead to generation of the aberrant readers in CRC. Wang et al. (165) have identified a novel lncRNA LINRIS to stabilize IGF2BP2 via LINRIS/IGF2BP2/MYC axis and promote cell proliferation in CRC. Mechanistically, the elevated level of LINRIS in the CRC patients with unfavorable prognostic could act on IGF2BP2 and protect it from K139 ubiquitination and autophagy degradation, and maintain its stability. The upregulated IGF2BP2 subsequently promotes the expression of its downstream target MYC mRNA, and enhances the MYC-mediated glycolysis in CRC, which eventually leads to progression of CRC. Inhibition of this axis by GATA3 may provide a potential therapeutic strategy for CRC.

Recently, Ni et al. showed another lncRNA involved in the YAP signaling pathway during CRC progression via the GAS5/YAP/YTHDF3 axis (166). They found GAS5 is downregulated in most of CRC tissues and is negatively correlated with the protein levels of YAP and YTHDF3, while the increased YTHDF3 is a significant prognostic factor for poor overall survival in CRC patients (146). Mechanistically, downregulation of GAS5 inhibits phosphorylation of YAP and attenuates its ubiquitination and degradation. The increased YAP further promotes expression level of YTHDF3, however, the downstream regulatory pathway of YTHDF3 that facilitates CRC progression is unclear.

Additionally, YTHDF1 is reported to be overexpressed in CRC and plays a vital oncogenic role in CRC (146, 167). Silencing YTHDF1 not only reduces the number of colon spheres but also causes significant downregulation of cancer stem cell markers, including CD44, CD133, OCT4, ALDH1, and Lgr5 in CRC cells. These findings indicate that YTHDF1 plays a key role in maintaining CRC stemness, which is analogous to the role of METTL3 in CRC (145). YTHDF1 is found to regulate the Wnt/β-Catenin pathway in CRC as well (167). Silencing YTHDF1 leads to reduction of the expressions of the nonphospho (active)-β-catenin and the Wnt/β-catenin downstream targets, including c-JUN, CCND1, and CD44, and thus downregulates the β-catenin nuclear signals activity.

**FIGURE 3** | The potential therapeutic strategies for the GICs with abnormal methylation regulators or levels. The aberrant methylation regulators, abnormal methylation levels, and the mutations that lead to the gain or loss of key methylation sites contribute partly in tumorigenesis, progression, and drug resistance in GICs. The potential therapeutic strategies include the small molecule inhibitors of the regulators and the targeted fusion proteins that based on CRISPR/Cas 13 system. FTO, fat mass and obesity-associated protein; NGICs, normal gastrointestinal cells; GICCs, gastrointestinal cancer cells; gRNA, guide RNA; dCas13, inactive Cas13 enzyme; MA, meclofenamic acid; R-2HG, R-2-hydroxyglutarate.
Other Gastric Cancer/Colorectal Cancer-Promoting Mechanisms Related to Methylation

Recent study has revealed that the m6A modification in a circular RNA (circRNA), circNSUN2 that maps to the chromosome 5p15 amplicon in CRC, has an important role for promoting CRC liver metastasis (168). Mechanically, circNSUN2 contains an m6A motif within its exon 5-exon 4 junction sequence where it can be modified by METTL3, and then YTHDC1 facilitates the nuclear export of the circNSUN2. In cytoplasm, circNSUN2 stabilizes its target, the polycomb repressive complex; LINRIS, Long Intergenic Noncoding RNA for IGF2BP2 Stability; *has been identified to be associated with CRC metastasis (168). Mechanically, circNSUN2 contains an m6A motif in its 5p15 amplicon in CRC, has an important role for promoting CRC liver metastasis. However, it is unknown how circNSUN2 regulates the metastasis. Further, they showed that either silencing METTL3 by small interfering RNA (siRNA), or inhibiting RNA methylation with neplanocin A, or suppressing ceramide glycosylation mechanism is able to re-sensitize the resistant CRC cells to anticancer drugs. Recently, Tian et al. (169) revealed another type of mutations that are related to the m6A modification, the missense variant rs8100241 (G > A) located in ANKLE1. Overexpression of the rs8100241[A] allele significantly increased the ANKLE1 m6A level that was catalyzed by writers METTL3/14 and WTAP and recognized by reader of YTHDF1, thus the dysregulated ANKLE1 protein is facilitated compared to that of rs8100241[G] allele, which is significantly related to susceptibility of CRC.

**TABLE 3 | Relationship between aberrant regulators and GICs**

| Cancer types | Regulator | Role in RNA modification | Abnormal change | Results | Mechanisms/targets | Ref |
|--------------|-----------|--------------------------|----------------|---------|--------------------|-----|
| GC METTL3    | Writer    | Upregulated              | Poor prognosis | METTL3/m6A/ZMYM1/ELAVL1/E-cadherin/EMT axis | (139) |
|              |           |                          |                | METTL3/m6A/HDFG/IGF2BP3 axis | (140) |
|              |           |                          |                | METTL3/m6A/SEC62/IGF2BP1 axis | (141) |
|              |           |                          |                | METTL3/m6A/AMMC axis | (143) |
|              |           |                          |                | METTL3/m6A/ARHGAP5 axis | (144) |
| WTAP and RMB15 | Writer   | Upregulated              | Poor prognosis; immune response | Unknown | (153-155) |
| METTL14      | Writer    | Downregulated            | Poor prognosis | METTL14/m6A/Wnt and PI3K-AKT axis | (156) |
| FTO          | Eraser    | Upregulated              | Poor prognosis | Unknown | (153, 155) |
| ALKBH5       | Eraser    | Upregulated              | Poor prognosis | ALKBH5/m6A/lncRNA NEAT1/EZH2 axis | (156, 162) |
| ALKBH5       | Eraser    | Upregulated              | Poor prognosis | ALKBH5/m6A/lncRNA NEAT1/EZH2 axis | (156, 162) |
| CRC METTL3   | Writer    | Upregulated              | Poor prognosis | METTL3/m6A/ARHGAP5 axis | (144) |
| METTL14      | Writer    | Downregulated            | Poor prognosis | METTL14/m6A/lncRNA XIST/YTHDF2 axis | (158) |
| FTO          | Eraser    | Downregulated            | Poor prognosis | FTO/m6A/tumor stemness axis | (146, 164) |
| ALKBH5       | Eraser    | Downregulated            | Poor prognosis | ALKBH5/m6A/lncRNA RP11/hnRNP2B1/E-ligases/E2E1 axis | (163) |
| IGF2BP2      | Reader    | Upregulated              | Poor prognosis | IncRNA LINRIS/IGF2BP2/IGF2BP2 axis | (165) |
| YTHDF3       | Reader    | Upregulated              | Poor prognosis | IncRNA GASS/YAP1/YTHDF3 axis | (166) |
| YTHDF3       | Reader    | Upregulated              | Poor prognosis | YTHDF3/m6A/β-Catenin and tumor stemness axis | (167) |

**POTENTIAL THERAPEUTIC STRATEGIES**

In view of the relationship between methylation modifications and tumors, new tumor treatment strategies have been explored. Meclofenamic acid (MA), the non-steroidal anti-inflammatory drug, was found to compete with FTO binding for the m6A-containing nucleic acid and functions as FTO inhibitor (170). R-2-hydroxyglutarate (R-2HG), generated from mutant isocitrate dehydrogenase 1/2 (IDH1/2) enzymes, was also found to inhibit FTO activity and increase the m6A level in cells, which in turn resistance in CRC. Further, they showed that either silencing METTL3 by small interfering RNA (siRNA), or inhibiting RNA methylation with neplanocin A, or suppressing ceramide glycosylation mechanism is able to re-sensitize the resistant CRC cells to anticancer drugs. Recently, Tian et al. (169) revealed another type of mutations that are related to the m6A modification, the missense variant rs8100241 (G > A) located in ANKLE1. Overexpression of the rs8100241[A] allele significantly increased the ANKLE1 m6A level that was catalyzed by writers METTL3/14 and WTAP and recognized by reader of YTHDF1, thus the dysregulated ANKLE1 protein is facilitated compared to that of rs8100241[G] allele, which is significantly related to susceptibility of CRC.

---

**TABLE 3 | Relationship between aberrant regulators and GICs*.

**GC, gastric cancer; CRC, colorectal cancer; writers, methyltransferases; erasers, demethylases; readers, the proteins that bind to methylation modifications; m6A, N6-methyladenosine; m1A, N1-methyladenosine; METTL3/14, methyltransferase-like3/14; WTAP, Wilms tumor 1-associated protein; RBM15, RNA-binding motif protein 15; FTO, fat mass and obesity-associated protein; ALKBH3/5, AlkB homolog 3/5; hnRNP2B1, heterogeneous nuclear ribonucleoprotein A2/B1; IncRNA, long non-coding RNA; miRNA, micro RNA; ZMYM1, zinc finger MYM-type containing 1; EMT, epithelial-mesenchymal transition; HDGF, hepatoma derived growth factor; SOX2, SRY (sex determining region Y)-box 2; HK2, Hexokinase 2; GLUT1, glucose transporter type 1; CCNE1, cyclin E1; XIST, X-inactive specific transcript; YAP1, Yes-associated protein 1; NEAT1, nuclear paraspeckle assembly transcript 1; EZH2, a subunit of the polycomb repressive complex; LINRIS, Long Intergenic Noncoding RNA for IGF2BP2 Stability; * has been identified to be associated with CRC metastasis.**
decreases the stability of MYC/CEBPA and thus block the MYC pathways (171). Recently, two synthetic high-efficient FTO inhibitors are identified. Chen et al. (172) have developed two potent FTO inhibitors FB23 and FB23-2 and showed that they could directly bind to FTO and selectively block the m^6^A demethylase activity of FTO. Subsequently, they further developed two others promising FTO inhibitors, namely CS1 and CS2, which exhibit strong anti-tumor effects in multiple types of cancers. For leukemia cells, FTO inhibitors cannot only block the signal axis of FTO/m^6^A/MYC/CEBPA and inhibit the self-renewal of cancer stem cells, but also suppress the expression of immune checkpoint LILRB4 and immune evasion thus enhancing the cytotoxicity of T cells (173). However, the inhibitors of other m^6^A regulators such as METTL3, METTL14, or WTAP have not been systematically developed. Moreover, targeted RNA demethylation or methylation by the engineered dCas13-containing fusion proteins may hold the potential to develop a treatment regimen for GICs (174–176) (Figure 3).

**CONCLUSIONS AND FUTURE PERSPECTIVE**

Since 2011, extensive studies have worked on the methylation modifications in RNAs, providing an extensive and accumulating database including m^6^A, m^6^Am, and m^1^A. The formation of m^1^A, m^6^A, and m^6^Am is no substantial correlated, and the roles of m^6^Am and m^1^A are partly similar to that of m^6^A, by which the m^6^Am and m^1^A modifications are demethylated by FTO. It would be interesting to measure the interference produced by m^6^Am and m^1^A during the m^6^A exploration process.

The dysregulation of RNA methylation has been linked to the abnormalities in the MYC pathway, the Wnt/β-Catenin pathway, the ErbB2 pathway, the PI3K-AKT pathway and EMT in many human cancers. For GICs, the upregulated METTL3 and erasers are mainly involved in the MAPK/ERK pathway, the CCNE1 pathway, the SOX2/tumor stemness pathway, glycolipid metabolism, and EMT and to facilitate CRC formation and progression, whereas the low expression of METTL14 mediates the lncRNA XIST axis and the miR-375/YAP1 and SP1 axis to promote CRC progression. Moreover, the upregulated readers, IGF2BP2, YTHDF3, and YTHDF1, represent as poor prognosis factors in CRC by regulating the lncRNA LINRIS/IGF2BP2/MYC/glycolysis axis, the lncRNA GASS/YAP/YTHDF3 axis and the YTHDF1/Wnt/β-Catenin and tumor stemness pathway respectively (Table 3). Mutations that cause the gain of methylation sites, including the point-mutated codon 273 (G > A) of p53 pre-mRNA and the missense variant rs8100241 (G > A) located in ANKLE1, are also linked to tumorigenesis, progression and drug resistance in CRC.

However, there are some controversies and confusions in the RNA methylation: i) Binding mode of YTHDF proteins on different mRNAs or a single mRNA. ii) Affinity towards the m^6^A and m^6^Am sites by FTO. iii) mRNA stability affected by the m^6^Am modification. iv) The role of the m^6^A modification in RNA translation. v) Specificity of the targets regulated by the methylation regulators. vi) The distinguish expression signatures of both the writers and the erasers in certain type of GICs, and their downstream targets. viii) Inhibitors for METTL3 and readers.

**AUTHOR CONTRIBUTIONS**

GW and WH proposed these ideas and valuable comments, and QL drafted the manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work was supported in part by grants from the National Natural Science Foundation of China (82073869, 81701834, 81871994); Guandong Basic and Applied Basic Research Foundation (2019A050510019, 2019B151502063); Guandong Provincial Key Laboratory of Construction Foundation (2017B030314030, 2020B1212060034); Guangzhou Science and Technology Planning Program (202002020051, 201902020018); National Engineering Research Centre for New Drug and Drug ability Evaluation, Seed Program of Guangdong Province (2017B090903004).

**REFERENCES**

1. Roundtree IA, Evans ME, Pan T, He C. Dynamic RNA modifications in gene expression regulation. Cell (2017) 169(7):1187–200. doi: 10.1016/j.cell.2017.05.045
2. Pan T. Modifications and functional genomics of human transfer RNA. Cell Res (2018) 28(4):395–404. doi: 10.1038/s41422-018-0013-y
3. Taoka M, Nobe Y, Yamaki Y, Sato K, Ishikawa H, Izumikawa K, et al. Landscape of the complete RNA chemical modifications in the human 80S ribosome. Nucleic Acids Res (2018) 46(18):9289–98. doi: 10.1093/nar/gky811
4. Linder B, Grozhik AV, Olarerin-George AO, Meydan C, Mason CE, Jaffrey SR. Single-nucleotide-resolution mapping of m^6^A and m^6^Am throughout the transcriptome. Nat Methods (2015) 12(8):767–72. doi: 10.1038/nmeth.3453
5. Yang Y, Fan X, Mao M, Song X, Wu P, Zhang Y, et al. Extensive translation of circular RNAs driven by N-methyladenosine. Cell Res (2017) 27(5):626–41. doi: 10.1038/cr.2017.31
6. Liu N, Dai Q, Zheng G, He C, Parisien M, Pan T. N(6)-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions. Nature (2015) 518(7540):560–4. doi: 10.1038/nature14234
7. Alarcón CR, Lee H, Goodarzi H, Halberg N, Tavazoie SF. N6-methyadenosine marks primary microRNAs for processing. Nature (2015) 519(7544):482–5. doi: 10.1038/nature14281
8. Helm M, Motorin Y. Detecting RNA modifications in the epitranscriptome: predict and validate. Nat Rev Genet (2017) 18(5):275–91. doi: 10.1038/nrg.2016.169
9. Bocciolatto P, Machnicka MA, Purta E, Pietkowska P, Baginski B, Wierci TK, et al. MODOMICS: a database of RNA modification pathways. 2017 update. Nucleic Acids Res (2018) 46(D1):D363–7. doi: 10.1093/nar/gka1030
10. Arango D, Sturgill D, Albusnai N, Dillman AA, Sweet TJ, Hanson G, et al. Acetylation of cytidine in mRNA promotes translation efficiency. Cell (2018) 175(7):1872–86. doi: 10.1016/j.cell.2018.10.030

11. Grozhik AV, Jaffrey SR. Distinguishing RNA modifications from noise in epitranscriptome maps. Nat Chem Biol (2018) 14(3):215–25. doi: 10.1038/nchembio.2546

12. Gilbert WV, Bell TA, Schaenning C. Messenger RNA modifications: form, distribution, and function. Science (New York NY) (2016) 352(6292):1408–12. doi: 10.1126/science.aad8711

13. Desrosiers R, Friderici K, Rottman F. Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. Proc Natl Acad Sci U S A (1974) 71(10):3971–5. doi: 10.1073/pnas.71.10.3971

14. Perry RP, Kelley DE. Existence of methylated messenger RNA in mouse L cells. Cell (1974) 1:37–42. doi: 10.1016/0092-8674(74)90153-6

15. Wei CM, Gershovitz A, Moss B. Methylated nucleotides block 5’ terminus of HeLa cell messenger RNA. Cell (1975) 4(4):379–86. doi: 10.1016/0092-8674(75)90158-0

16. Niu Y, Wan A, Lin Z, Lu X, Wan GN. N (6)-methyladenosine modification: a novel pharmacological target for anti-cancer drug development. Acta Pharm Sin B (2018) 8(6):833–43. doi: 10.1016/j.apsb.2018.06.001

17. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin (2018) 68(6):394–424. doi: 10.3322/caac.21492

18. Jaffrey SR, Kharas MG. Emerging links between mA and misregulated mRNA splicing. Nat Rev Genet (2014) 15(5):293–306. doi: 10.1038/nrg3724

19. Jia G, Fu Y, Zhao X, Dai Q, Zheng G, Yang Y, et al. N6-methyladenosine in mRNA causes splicing but do specify cytoplasmic turnover. Nat Commun (2014) 5:1918–19. doi: 10.1038/ncomms1918

20. Zheng G, Dahl JA, Niu Y, Fedorcsak P, Huang C-M, Li CJ, et al. ALKBH5 is a Puriﬁcation and cDNA cloning of the AdoMet-binding subunit of the human mRNA (6)-adenosine methyltransferase. RNA (New York NY) (1997) 3(1):1233–47.

21. Bujnicki JM, Feder M, Radlinska M, Blumenthal RM. Structure prediction and phylogenetic analysis of a functionally diverse family of proteins homologous to the MT-A70 subunit of the human m(6)A methyltransferase. J Mol Biol (2002) 353(2):341–45. doi: 10.1016/s0022-2836(02)01131-0

22. Feng J, Zeng G, Chen L, Zhang Y, Chen J, Yui J, et al. VIRMA mediates nuclear RNA N6-adenosine methylation. Nucleic Acids Res (2018) 46:3167–77. doi: 10.1093/nar/gky180

23. Harper JE, Micelli SM, Roberts RJ, Manley JL. Sequence speciﬁcity of the human mRNA N6-adenosine methylase in vitro. Nucleic Acids Res (1990) 18(19):5735–41. doi: 10.1093/nar/18.19.5735

24. Ke S, Pandya-Jones A, Saito Y, Fak JJ, Vágóe CB, Geula S, et al. m6A RNA modifications are deposited in nascent pre-mRNA and are not required for splicing but do specify cytoplasmic turnover. Genes Dev (2017) 31(10):990–1006. doi: 10.1101/gad.301036.117

25. Bokar JA, Rath-Shambaugh ME, Ludwiczak R, Narayan P, Rottman F. Characterization and partial puriﬁcation of mRNA N6-adenosine methyltransferase from HeLa cell nuclei. Internal mRNA methylation requires a multisubunit complex. J Biol Chem (1994) 269(26):17697–704. doi: 10.1074/jbc.269.26.17697

26. Rottman FM, Bokar JA, Narayan P, Shambaugh ME, Ludwiczak R. N6-adenosine methylation in mRNA: substrate speciﬁcity and enzyme complexity. Biochemistry (1994) 33(12):1109–14. doi: 10.1021/bi00038a004

27. Bokar JA, Shambaugh ME, Polayes D, Madera AG, Rottman FM. Purification and cDNA cloning of the AdoMet-binding subunit of the human mRNA (6)-adenosine-methyltransferase. RNA (New York NY) (1997) 3(1):1233–47.

28. Liu H, Begik O, Lucas MC, Ramirez JM, Mason CE, Wiener D, et al. In vivo chemical approach for detection of N-methyladenosine. J Mol Biol (2010) 407(4):865–876. doi: 10.1016/j.jmb.2010.05.003

29. Bokar JA, Shambaugh ME, Rath-Shambaugh ME, Ludwiczak R. N6-adenosine methylation in mRNA: substrate speciﬁcity and enzyme complexity. Biochemistry (1994) 33(12):1109–14. doi: 10.1021/bi00038a004

30. Liu H, Begik O, Lucas MC, Ramirez JM, Mason CE, Wiener D, et al. Accurate detection of mA RNA modiﬁcations in native RNA sequences. Nat Commun (2019) 10(1):4079. doi: 10.1038/s41467-019-11713-9

31. Rottman F, Shatkin AJ, Perry RP. Sequence containing methylated nucleotides at the 5’ termini of messenger RNAs: possible implications for processing. Cell (1974) 7(3):197–9. doi: 10.1016/0092-8674(74)90151-7

32. Perry RP, Kelley DE, Friderici K, Rottman F. The methylated constituents of L cell messenger RNA: evidence for an unusual cluster at the 5’ terminus. Cell (1975) 4(4):387–94. doi: 10.1016/0092-8674(75)90159-2

33. Li et al. Methyladenosine Modification and Gastrointestinal Cancers
53. Patil DP, Chen CK, Pickering BF, Chow A, Jackson C, Guttmann M, et al. m(6)A RNA methylation promotes XIST-mediated transcriptional repression. Nature (2016) 537(7620):369–73. doi:10.1038/nature19342

54. Aguilo F, Zhang F, Sancho A, Fidalgo M, Di Cecilia S, Vashisth A, et al. Coordination of m(6)A mRNA methylation and gene transcription by ZFP217 regulates pluripotency and reprogramming. Cell Stem Cell (2015) 17(6):689–704. doi:10.1016/j.stem.2015.09.005

55. Bertero A, Brown S, Madrigal P, Osnato A, Ortmann D, Yiangou L, et al. The DNA-repair protein AlkB, EGL-9, and leprecan cification and Gastrointestinal Cancers.

56. Jia G, Yang C-G, Yang S, Jian X, Yi C, Zhou Z, et al. Oxidative demethylation by mouse and human FTO. Nat Chem Biol (2019) 15(6):689–94. doi:10.1016/j.chembiol.2019.04.007

57. Brown JA, Kinzig CG, DeGregorio SJ, Steitz JA. Methylation-infer to generate the observed complex of the YTH domain in complex with N6-methyladenosine RNA: a reader of mRNA. Nat Commun (2011) 2:315. doi:10.1038/ncomms12626

58. van Tran N, Ernst FGM, Hawley BR, Zorbas C, Ulynnck N, Hackert P, et al. The human 185 RNA m6A methyltransferase METTL5 is stabilized by TRMT112. Nucleic Acids Res (2019) 47(15):7719–33. doi:10.1093/nar/gkz619

59. Hartmann AM, Nayler O, Stamm S. The ER repeat protein YT521-B mediates nuclear export of N-methyladenosine methylated mRNAs. Elife (2017) 6. doi:10.7554/eLife.31311

60. van Tran N, Ernst FGM, Hawley BR, Zorbas C, Ulynnck N, Hackert P, et al. The human 185 RNA m6A methyltransferase METTL5 is stabilized by TRMT112. Nucleic Acids Res (2019) 47(15):7719–33. doi:10.1093/nar/gkz619

61. Bertero A, Brown S, Madrigal P, Osnato A, Ortmann D, Yiangou L, et al. The DNA-repair protein AlkB, EGL-9, and leprecan cification and Gastrointestinal Cancers.
104. Furuichi Y, Morgan M, Shatkin AJ, Jelinek W, Salditt-Georgieff M, Darnell J, Adams JM, Cory S. Modifi cation of the PRMT1 catalyzes m6Am methylation in U2 snRNA to regulate pre-mRNA splicing. Nucleic Acids Res (2020) 48(16):9250–61. doi: 10.1093/nar/gkaa504

105. Mauer J, Luo X, Blanpied A, Xiao X, Grothak AV, Patil DP, et al. Reversible methylation of m6Am in the 5′ cap controls mRNA stability. Nature (2017) 541 (7637):371–5. doi: 10.1038/nature21022

106. Zhang X, Wei LH, Wang Y, Xiao Y, Liu J, Zhang W, et al. Structural insights into FTO’s catalytic mechanism for the demethylation of multiple RNA substrates. Proc Natl Acad Sci U S A (2019) 116(8):2919–24. doi: 10.1073/pnas.1805741116

107. Wei J, Liu F, Lu Z, Fei Q, Ai Y, He PC, et al. Differential mA, m6A, and m6Am Demethylation Mediated by FTO in the Cell Nucleus and Cytoplasm. Mol Cell (2018) 71(6):973–85.e5. doi: 10.1016/j.molcel.2018.08.011

108. Sendinc E, Valle-Garcia D, Dhall A, Chen H, Henriques T, Navarrete-Perea J, et al. PCF1F Catalyzes m6Am mRNA Methylation to Regulate Gene Expression. Mol Cell (2019) 75(3):620–30.e9. doi: 10.1016/j.molcel.2019.05.030

109. Dunn DB. The occurrence of 1-methyladenine in ribonucleic acid. Biochim Biophys Acta (1941) 6:498–200. doi: 10.1006/0006-3002(61)90688-0

110. Macon JB, Woldfenden R. 1-Methyladenosine. Dimroth rearrangement and irreversible reduction. Biochemistry (1968) 7(10):3453–8. doi: 10.1021/bi008040a

111. El Yaacoubi B, Baily M, de Crecy-Lagard V. Biosynthesis and function of posttranscriptional modifications of transfer RNAs. Annu Rev Genet (2012) 46(1):23–41. doi: 10.1146/annurev-genet-110711-155641

112. Sharma S, Watzinger P, Kötter P, Entian KD. Identi fi cation of a novel methyltransferase, Bm2, responsible for the N-1-methyl-adenosine base modifi cation of 25S rRNA in Saccharomyces cerevisiae. Nucleic Acids Res (2013) 41(10):5428–43. doi: 10.1093/nar/gkt195

113. Dominissini D, Nachtergaele S, Moshitch-Moshkovitz S, Peer E, Kol N, Ben-Haim MS, et al. The dynamic N(1)-methyladenosine methylome in eukaryotic messenger RNA. Nature (2016) 530(7591):441–6. doi: 10.1038/nature16998

114. Li X, Xiong X, Wang K, Wang L, Shu X, Ma S, et al. Transcriptome-wide mapping reveals reversible and dynamic N(1)-methyladenosine methylome. Nucleic Acids Res (2017) 45(1):652–64. doi: 10.1093/nar/gkw1478

115. Li X, Xiong X, Zhang M, Wang K, Chen Y, Zhou J, et al. Base-resolution mapping reveals distinct mA methylome in nuclear- and mitochondrial-encoded transcripts. Mol Cell (2017) 68(5):993–1005.e9. doi: 10.1016/j.molcel.2017.10.019

116. Safrà M, Sas-Chen A, Nir R, Winkler R, Nachshon A, Bar-Yaakov D, et al. The mA landscape on cytosolic and mitochondrial mRNA at single-base resolution. Nature (2017) 551(7679):251–5. doi: 10.1038/nature24456

117. Chouj T, Suzuki T. Trm61B is a methyltransferase responsible for 1-methyladenosine at position 58 of human mitochondrial (t)RNAs. RNA (New York NY) (2012) 18(12):2269–76. doi: 10.1012/j.molcel.2013.05600.112

118. Ougland R, Zhang C-M, Liiv A, Johansen RF, Seeberg E, Hou YM, et al. AlkB restores the biological function of mRNA and tRNA inactivated by chemical mutagenesis. Proc Natl Acad Sci U S A (2011) 108(9):2855–60. doi: 10.1073/pnas.1013761108

119. Ougland R, Zhang C-M, Liiv A, Johansen RF, Seeberg E, Hou YM, et al. AlkB restores the biological function of mRNA and tRNA inactivated by chemical mutagenesis. Proc Natl Acad Sci U S A (2011) 108(9):2855–60. doi: 10.1073/pnas.1013761108
135. Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell (2009) 136(4):731–45. doi: 10.1016/j.cell.2009.01.042
136. Zheng Q, Gan H, Yang F, Yao Y, Hao F, et al. Cytoplasmic mA reader YTHDF3 inhibits trophoblast invasion by downregulation of mA-methylated IGFR1. Cell Discov (2020) 6:12. doi: 10.1038/s41421-020-0144-4
137. Seo KW, Kleiner RE. YTHDF2 Recognition of N-Methyladenosine (mA)-Modified RNA Is Associated with Transcript Destabilization. ACS Chem Biol (2020) 15(1):132–9. doi: 10.1021/acschembio.9b00655
138. He L, Li H, Wu A, Peng Y, Shu G, Yin G, et al. Functions of N6-methyladenosine and its role in cancer. Mol Cancer (2019) 18(1):176. doi: 10.1186/s12943-019-1019-2
139. Yue B, Yue B, Song C, Yang L, Cui R, Cheng X, Zhang Z, et al. METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer. Mol Cancer (2019) 18(1):142. doi: 10.1186/s12943-019-1065-4
140. Wang Q, Chen C, Ding Q, Zhao Y, Wang Z, Chen J, et al. METTL3-mediated mA modification of HDG6 mRNA promotes cancer progression and has prognostic significance. Gut (2019) 67(7):1193–205. doi: 10.1136/gutjnl-2019-319639
141. He H, Wu W, Sun Z, Chai L, et al. MIR-4429 prevented gastric cancer progression through targeting METTL3 to inhibit mA-caused stabilization of SEC62. Biochem Biophys Res Commun (2019) 517(4):581–7. doi: 10.1016/j.bbrc.2019.07.058
142. Liu T, Yang S, Sui J, Xu Y, Cheng YP, Shen B, et al. Dysregulated N6-methyladenosine methylation writer METTL3 contributes to the proliferation and migration of gastric cancer. J Cell Physiol (2020) 235 (1):548–62. doi: 10.1002/jcp.28994
143. Yang D-D, Chen Z-H, Yu K, Lu JH, Wu QN, Wang Y, et al. METTL3 Promotes the Progression of Gastric Cancer via Targeting the MYC Pathway. Front Oncol (2020) 10:115. doi: 10.3389/fonc.2020.00115
144. Zhi L, Zhi Y, Han S, Chen M, Song P, Dai D, et al. Impaired autophagic degradation of IncRNA ARHGAP5-A5I promotes chemoresistance in gastric cancer. Cell Death Dis (2019) 10(6):383. doi: 10.1038/s41419-19-1958-2
145. Li T, Hu PS, Zuo Z, Lin JF, Li X, Wu QN, et al. METTL3 facilitates tumor progression via an mA-IGF2BP2-dependent mechanism in colorectal carcinoma. Mol Cancer (2019) 18(11):112. doi: 10.1186/s12943-019-1038-7
146. Liu X, Liu L, Dong Z, Li J, Yu Y, Chen X, et al. Expression patterns and prognostic value of mA-related genes in colorectal cancer. Am J Transl Res (2019) 11(7):3972–91.
147. Peng W, Li J, Chen R, Gu Q, Yang P, Qian W, et al. Upregulated METTL3 promotes metastasis of colorectal Cancer via miR-1246/SNPP2/MAPK signaling pathway. J Exp Clin Cancer Res (2019) 38(1):393. doi: 10.1186/s13046-019-1408-4
148. Shen C, Xuan B, Yan T, Ma Y, Xu P, Tian X, et al. mA-dependent glycolysis enhances colorectal cancer progression. Mol Cancer (2020) 19(1):72. doi: 10.1186/s12943-020-01190-w
149. Zhu W, Si Y, Xu J, Lin Y, Wang J-Z, Cao M, et al. Methyltransferase like 3 promotes colorectal cancer proliferation by stabilizing CCNE1 mRNA in an mA-dependent manner. J Cell Mol Med (2020) 24(3):3532–33. doi: 10.1111/jcmm.15042
150. Deng R, Cheng Y, Ye S, Zhang J, Huang R, Li P, et al. mA methyltransferase METTL3 suppresses colorectal cancer proliferation and migration through p38/ERK pathways. Oncotarget Ther (2019) 12:4391–402. doi: 10.2147/OTT.S201052
151. Uddin MB, Roy KR, Hoasain SB, Khiste SK, Hill RA, Jotis SD, et al. An N-methyladenosine at the transited codon 273 of p53 pre-mRNA promotes the expression of R273H mutant protein and drug resistance of cancer cells. Biochem Pharmacol (2019) 160:134–45. doi: 10.1016/j.bcp.2018.12.014
152. Boumahdi S, Diessens G, Lapouge G, Lorive S, Nasser D, Le Mercier M, et al. SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma. Nature (2014) 511(7508):246–50. doi: 10.1038/nature13305
153. Guan K, Liu X, Li J, Ding Y, Li J, Cui G, et al. Expression Status And Prognostic Value Of M6A-associated Genes in Gastric Cancer. J Cancer (2020) 11(10):3027–40. doi: 10.7150/jca.40866
154. Li H, Su Q, Li B, Lan L, Wang C, Li W, et al. High expression of WTAP leads to poor prognosis of gastric cancer by influencing tumour-associated T lymphocyte infiltration. J Cell Mol Med (2020) 24(8):4452–65. doi: 10.1111/jcmm.15104
155. Su Y, Huang J, Hu J. mA RNA Methylation regulators contribute to malignant progression and have clinical prognostic impact in gastric cancer. Front Oncol (2019) 9:1038. doi: 10.3389/fonc.2019.01038
176. Wilson C, Chen PJ, Miao Z, Liu DR. Programmable mA modification of cellular RNAs with a Cas13-directed methyltransferase. *Nat Biotechnol* (2020) 38(12):1431–40. doi: 10.1038/s41587-020-0572-6

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.